Get the Stockscreener App
1.455
1.75%
0.025
Alector Inc stock is traded at $1.455, with a volume of 206.43K.
It is up +1.75% in the last 24 hours and up +1.04% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.43
Open:
$1.43
24h Volume:
206.43K
Relative Volume:
0.29
Market Cap:
$145.49M
Revenue:
$100.56M
Net Income/Loss:
$-119.05M
P/E Ratio:
-1.1829
EPS:
-1.23
Net Cash Flow:
$-231.16M
1W Performance:
-2.35%
1M Performance:
+1.04%
6M Performance:
-16.86%
1Y Performance:
-70.37%
1-Day Range:
$1.42
$1.47
1-Week Range:
$1.42
$1.595
52-Week Range:
$0.87
$6.37
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.455 | 155.99M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.26 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.69 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.49 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.61 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.02 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Should I hold or sell Alector Inc. stock in 2025Invest smarter with daily stock recommendations - Jammu Links News
What makes Alector Inc. stock price move sharplyBoost your wealth with consistent growth stocks - Jammu Links News
How strong is Alector Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
What institutional investors are buying Alector Inc. stockPowerful profit generation - Jammu Links News
Is Alector Inc. a good long term investmentInvest smarter with actionable market insights - Jammu Links News
How does Alector Inc. generate profit in a changing economyAchieve breakthrough financial results today - Jammu Links News
What is the dividend policy of Alector Inc. stockIdentify undervalued stocks ready to soar - Jammu Links News
What is Alector Inc. company’s growth strategyBuild a diversified portfolio for stability - Jammu Links News
Alector Inc. Stock Analysis and ForecastGet exclusive access to professional stock picks - Jammu Links News
How does Alector Inc. compare to its industry peersDiscover high-impact stocks for growth - Jammu Links News
Is it the right time to buy Alector Inc. stockHigh-yield investments - Jammu Links News
Why is Alector Inc. stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What are analysts’ price targets for Alector Inc. in the next 12 monthsBuild a diversified portfolio for steady profits - Jammu Links News
How to build a custom watchlist for Alector Inc.Sector Rotation Strategy for Smart Traders - Newser
Market reaction to Alector Inc.’s recent newsRSI and MACD Signal Summary with Trends - Newser
Identifying reversal signals in Alector Inc.Free AI Powered High Return Stock Calls - Newser
Why Alector Inc. stock attracts strong analyst attentionPortfolio Risk Distribution Analysis Tool - Newser
Alector's Latozinemab Study Advances Neurodegenerative Disease Treatment - AInvest
When is Alector Inc. stock expected to show significant growthExpert Picks Watchlist For Every Investor - Jammu Links News
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment - TipRanks
What is the risk reward ratio of investing in Alector Inc. stockFinancial News Review For Consistent Profits - Jammu Links News
Risk adjusted return profile for Alector Inc. analyzedReal Chart Based Opportunity Identification - Newser
How to recover losses in Alector Inc. stockShort-Term Stock Trend Forecast Guide - Newser
Is Alector Inc. stock entering bullish territoryRSI and MACD Signal Summary with Trends - Newser
Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation - Insider Monkey
Alector Inc. Company Revenue and Profit Trends: A Deep DiveHigh Conviction Screener with Trend Matching - Newser
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call - 富途牛牛
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call | ALEC Stock News - GuruFocus
Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update - Quiver Quantitative
Is Alector Inc. a candidate for recovery playShort-Term Growth Watch with Signal Prediction - Newser
Will Alector Inc. continue its uptrendROI Focused Setup With Drawdown Analysis - Newser
Competitive Positioning of Alector Inc.: Is It Leading or LaggingNews Based Entry Opportunity Alerts Detected - metal.it
How Alector Inc. stock performs during market volatilityMinimal Risk Growth Investment Opportunity Analysis - Newser
Is a relief rally coming for Alector Inc. holdersFree Pattern Detection for Entry Confirmation - Newser
Regression analysis insights on Alector Inc. performancePredictive Screener for Daily Trade Watch - Newser
Is Alector Inc. stock poised for growthIntraday Strategy with Real Time Monitoring - Newser
Can Alector Inc. rally from current levelsOversold Reversal Picks with Buy Zone - Newser
Detecting support and resistance levels for Alector Inc.Day Trading Setup and Momentum Analysis - Newser
Alector, Inc. shares rise 1.86% after-hours following GSK's dementia research progress. - AInvest
Technical Charts Suggest Momentum Shift in Alector Inc.Breakout Momentum Picks With Protection Outlined - metal.it
Top Risks to Consider Before Buying Alector Inc. StockBuy List With Technical Entry Triggers - Newser
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):